litlas
Log inCreate account

Edo Vellenga

Active 1982–2024

145
Papers
21,355
Citations
95
h-index
145
i10-index

Citations

Citations per year for Edo Vellenga1943: 1 citations1982: 2 citations1983: 2 citations1984: 3 citations1985: 2 citations1986: 4 citations1987: 7 citations1988: 16 citations1989: 42 citations1990: 33 citations1991: 24 citations1992: 25 citations1993: 25 citations1994: 15 citations1995: 20 citations1996: 14 citations1997: 19 citations1998: 29 citations1999: 29 citations2000: 58 citations2001: 74 citations2002: 77 citations2003: 109 citations2004: 89 citations2005: 131 citations2006: 143 citations2007: 130 citations2008: 149 citations2009: 142 citations2010: 165 citations2011: 206 citations2012: 193 citations2013: 176 citations2014: 164 citations2015: 186 citations2016: 162 citations2017: 160 citations2018: 161 citations2019: 581 citations2020: 540 citations2021: 615 citations2022: 367 citations2023: 267 citations2024: 412 citations2025: 157 citations2026: 1 citations1944–1981: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,265 citing papers, 24.8% of this breakdownGermany: 700 citing papers, 7.7% of this breakdownUnited Kingdom: 654 citing papers, 7.2% of this breakdownNetherlands: 605 citing papers, 6.6% of this breakdownChina: 558 citing papers, 6.1% of this breakdownItaly: 518 citing papers, 5.7% of this breakdownFrance: 441 citing papers, 4.8% of this breakdownCanada: 321 citing papers, 3.5% of this breakdownSpain: 296 citing papers, 3.2% of this breakdownAustralia: 254 citing papers, 2.8% of this breakdownJapan: 216 citing papers, 2.4% of this breakdownSwitzerland: 189 citing papers, 2.1% of this breakdown
0%24.8%Other 23.1%

Institutions

Fields

  • Medicine67.6%
  • Biochemistry, Genetics and Molecular Biology24.5%
  • Immunology and Microbiology4.6%
  • Neuroscience0.9%
  • Agricultural and Biological Sciences0.4%
  • Computer Science0.3%
  • Other1.7%

Topics

  • Acute Myeloid Leukemia Research10.5%
  • Multiple Myeloma Research and Treatments3.9%
  • Hematopoietic Stem Cell Transplantation3.2%
  • Protein Degradation and Inhibitors2.7%
  • Epigenetics and DNA Methylation2.5%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment2.3%
  • Other74.9%

Coauthors

All papers

Open in search
  1. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Authors: Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, Guillermo Garcia‐Manero, Rena Buckstein, Valeria Santini, María Díez‐Campelo, Carlo Finelli, Mario Cazzola, Osman İlhan, Mikkael A. Sekeres, José Falantes, Beatriz Arrizabalaga, Flavia Salvi, Valentina Giai, Paresh Vyas, David Bowen, Dominik Selleslag, Amy E. DeZern, Joseph G. Jurcic, Ulrich Germing, Katharina S. Götze, Bruno Quesnel, Odile Beyne‐Rauzy, Thomas Cluzeau, Maria-Teresa Voso, Dominiek Mazure, Edo Vellenga, Peter L. Greenberg, Eva Hellström-Lindberg, Amer M. Zeidan, Lionel Adès, Amit Verma, Michael R. Savona, Abderrahmane Laadem, Aziz Benzohra, Jennie Zhang, Anita Rampersad, Diana Dunshee, Peter G. Linde, Matthew L. Sherman, Rami S. Komrokji, Alan F. List - New England Journal of Medicine 2020 cited by 537

  2. Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients

    Authors: Niels Grote Beverborg, IJsbrand T. Klip, Wouter C. Meijers, Adriaan A. Voors, Eline L. Vegter, Haye H. van der Wal, Dorine W. Swinkels, Joost van Pelt, André B. Mulder, Sjoerd K. Bulstra, Edo Vellenga, Massimo A. Mariani, Rudolf A. de Boer, Dirk J. van Veldhuisen, Peter van der Meer - Circulation Heart Failure 2018 cited by 268

  3. High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

    Authors: Bob Löwenberg, Gert J. Ossenkoppele, Wim van Putten, Harry C. Schouten, Carlos Graux, Augustin Ferrant, Pieter Sonneveld, Johan Maertens, Mojca Jongen‐Lavrencic, Marie von Lilienfeld‐Toal, Bart J. Biemond, Edo Vellenga, Marinus van Marwijk Kooy, Leo F. Verdonck, Joachim Beck, Hartmut Döhner, Aloïs Gratwohl, Thomas Pabst, Gregor Verhoef - New England Journal of Medicine 2009 cited by 822

  4. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

    Authors: Pau Montesinos, Juan Bergua, Edo Vellenga, Chelo Rayón, Ricardo Parody, Javier de la Serna, Ángel León, Jordi Esteve, Giuseppe Milone, Guillermo Debén, Concha Rivas, Marcos González, Mar Tormo, Joaquín Diaz‐Mediavilla, José D. González, Silvia Negri, Elena Amutio, Salut Brunet, Bob Löwenberg, Miguel Á. Sanz - Blood 2008 cited by 364

  5. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Authors: Hagop M. Kantarjian, Neil P. Shah, Jörge E. Cortes, Michele Baccarani, M B Agarwal, María Soledad Undurraga, Jianxiang Wang, Juan Julio Kassack Ipiña, Dong‐Wook Kim, Michinori Ogura, Carolina Pavlovsky, Christian Junghanß, Jorge Milone, Franck E. Nicolini, Tadeusz Robak, Jan Van Droogenbroeck, Edo Vellenga, M. Brigid Bradley‐Garelik, Chao Zhu, Andreas Hochhaus - Blood 2011 cited by 605

  6. The multifaceted role of autophagy in cancer and the microenvironment

    Authors: Hendrik Folkerts, Susan Hilgendorf, Edo Vellenga, Edwin Bremer, Valerie R. Wiersma - Medicinal Research Reviews 2018 cited by 203

  7. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

    Authors: Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griškevičius, Lidwine W. Tick, Mojca Jongen‐Lavrencic, Marinus van Marwijk Kooy, Marie-Christiane Vekemans, Walter J. F. M. van der Velden, Berna Beverloo, Lucienne Michaux, Carlos Graux, Dries Deeren, Okke de Weerdt, Joost W. J. van Esser, Mario Bargetzi, Saskia K. Klein, Alain Gadisseur, Peter E. Westerweel, Hendrik Veelken, Michael Gregor, Tobias Silzle, Daniëlle van Lammeren-Venema, Ine Moors, Dimitri Breems, Mels Hoogendoorn, Marie-Cecile J. C. Legdeur, Thomas Fischer, Juergen Kuball, Jan J. Cornelissen, Kimmo Porkka, Gunnar Juliusson, Peter Meyer, Martin Höglund, Bjørn Tore Gjertsen, Jeroen J. W. M. Janssen, Gerwin Huls, Jakob Passweg, Jacqueline Cloos, Peter J.M. Valk, Catharina Van Elssen, Markus G. Manz, Yngvar Fløisand, Gert J. Ossenkoppele - Blood Advances 2021 cited by 66

  8. Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis

    Authors: Vincent van den Boom, Henny Maat, Marjan Geugien, Aida Rodríguez López, Ana M. Sotoca, Jennifer Jaques, Annet Z. Brouwers-Vos, Fabrizia Fusetti, Richard W.J. Groen, Huipin Yuan, Anton C. Martens, Hendrik G. Stunnenberg, Edo Vellenga, Joost H.A. Martens, Jan Jacob Schuringa - Cell Reports 2015 cited by 151

  9. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

    Authors: Annemiek Broyl, Dirk Hose, Henk M. Lokhorst, Yvonne de Knegt, Justine Peeters, Anna Jauch, Uta Bertsch, Arjan Buijs, Marian Stevens‐Kroef, H. Berna Beverloo, Edo Vellenga, Sonja Zweegman, Marie-Josée Kersten, Bronno van der Holt, Laila el Jarari, George Mulligan, Hartmut Goldschmidt, Mark van Duin, Pieter Sonneveld - Blood 2010 cited by 338

  10. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

    Authors: David P. Steensma, Pierre Fenaux, Koen Van Eygen, Azra Raza, Valeria Santini, Ulrich Germing, Patricia Font, María Díez‐Campelo, Sylvain Thépot, Edo Vellenga, Mrinal M. Patnaik, Jun Ho Jang, Helen Varsos, Jacqueline Bussolari, Esther Rose, Laurie Sherman, Libo Sun, Ying Wan, Souria Dougherty, Fei Huang, Faye Feller, Aleksandra Rizo, Uwe Platzbecker - Journal of Clinical Oncology 2020 cited by 125

  11. Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse

    Authors: Dimitri Breems, Wim L.J. van Putten, Peter C. Huijgens, Gert J. Ossenkoppele, Gregor Verhoef, Leo F. Verdonck, Edo Vellenga, Georgine E. de Greef, E Jacky, J. van der Lelie, Marc Boogaerts, Bob Löwenberg - Journal of Clinical Oncology 2005 cited by 515

  12. Cytarabine Dose for Acute Myeloid Leukemia

    Authors: Bob Löwenberg, Thomas Pabst, Edo Vellenga, Wim van Putten, Harry C. Schouten, Carlos Graux, Augustin Ferrant, Pieter Sonneveld, Bart J. Biemond, Aloïs Gratwohl, Georgine E. de Greef, Leo F. Verdonck, M Schaafsma, Michael Gregor, Matthias Theobald, Urs Schanz, Johan Maertens, Gert J. Ossenkoppele - New England Journal of Medicine 2011 cited by 407

  13. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

    Authors: Hartmut Goldschmidt, H M Lokhorst, E K, Bronno van der Holt, Igor Wolfgang Blau, Sonja Zweegman, Katja Weisel, Edo Vellenga, Michael Pfreundschuh, Marie José Kersten, Christof Scheid, Sandra Croockewit, Reinier Raymakers, Dirk Hose, Anna Potamianou, A. Jauch, Jens Hillengaß, Marian Stevens‐Kroef, Marc‐Steffen Raab, Annemiek Broijl, H. Lindemann, Gerard M.J. Bos, Peter Brossart, Marinus van Marwijk Kooy, Paula F. Ypma, Ulrich Duehrsen, Ron Schaafsma, Uta Bertsch, Thomas Hielscher, L. e. Jarari, Hans Salwender, Pieter Sonneveld - Leukemia 2017 cited by 201

  14. Down-Regulation of E-Cadherin in Human Bronchial Epithelial Cells Leads to Epidermal Growth Factor Receptor-Dependent Th2 Cell-Promoting Activity

    Authors: Irene H. Heijink, P. Marcel Kies, Henk F. Kauffman, Dirkje S. Postma, Antoon J. M. van Oosterhout, Edo Vellenga - The Journal of Immunology 2007 cited by 181

  15. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

    Authors: Gerwin Huls, Dana Chiţu, Violaine Havelange, Mojca Jongen‐Lavrencic, Arjan A. van de Loosdrecht, Bart J. Biemond, Harm Sinnige, Beata Hodossy, Carlos Graux, Rien van Marwijk Kooy, Okke de Weerdt, Dimitri Breems, Saskia K. Klein, Jürgen Kuball, Dries Deeren, Wim Terpstra, Marie‐Christiane Vekemans, Gert J. Ossenkoppele, Edo Vellenga, Bob Löwenberg, the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) - Blood 2019 cited by 176

  16. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    Authors: Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Edo Vellenga, Annemiek Broyl, Igor Wolfgang Blau, Katja Weisel, Shulamiet Wittebol, Gerard M.J. Bos, Marian Stevens‐Kroef, Christof Scheid, Michael Pfreundschuh, Dirk Hose, Anna Jauch, Helgi van de Velde, Reinier Raymakers, M Schaafsma, Marie José Kersten, Marinus van Marwijk-Kooy, Ulrich Duehrsen, Walter Lindemann, Pierre W. Wijermans, Henk M. Lokhorst, Hartmut Goldschmidt - Journal of Clinical Oncology 2012 cited by 826

  17. The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis

    Authors: Bauke de Boer, Sofia Sheveleva, Katja Apelt, Edo Vellenga, André B. Mulder, Gerwin Huls, Jan Jacob Schuringa - Haematologica 2020 cited by 38

  18. Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones

    Authors: Bauke de Boer, Janine Prick, Maurien Pruis, Peter Keane, Maria Rosaria Imperato, Jennifer Jaques, Annet Z. Brouwers-Vos, Shanna M. Hogeling, Carolien M. Woolthuis, Marije T. Nijk, Arjan Diepstra, Sebastian K. Wandinger, Matthias Versele, Ricardo M. Attar, Peter N. Cockerill, Gerwin Huls, Edo Vellenga, André B. Mulder, Constanze Bonifer, Jan Jacob Schuringa - Cancer Cell 2018 cited by 106

  19. Protein quality control in the nucleolus safeguards recovery of epigenetic regulators after heat shock

    Authors: Maria Azkanaz, Aida Rodríguez López, Bauke de Boer, Wouter Huiting, Pierre‐Olivier Angrand, Edo Vellenga, Harm H. Kampinga, Steven Bergink, Joost H.A. Martens, Jan Jacob Schuringa, Vincent van den Boom - eLife 2019 cited by 75

  20. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia

    Authors: Gary Klein, Edo Vellenga, Marco W. Fraaije, Willem A. Kamps, Eveline S.J.M. de Bont - Critical Reviews in Oncology/Hematology 2004 cited by 343

  21. eFORGE: A Tool for Identifying Cell Type-Specific Signal in Epigenomic Data

    Authors: Charles E. Breeze, Dirk S. Paul, Jenny van Dongen, Lee M Butcher, John C. Ambrose, James E. Barrett, Robert Lowe, Vardhman K. Rakyan, Valentina Iotchkova, Mattia Frontini, Kate Downes, Willem H. Ouwehand, Jonathan Laperle, Pierre‐Étienne Jacques, Guillaume Bourque, Anke K. Bergmann, Reiner Siebert, Edo Vellenga, Sadia Saeed, Filomena Matarese, Joost H.A. Martens, Hendrik G. Stunnenberg, Andrew E. Teschendorff, Javier Herrero, Ewan Birney, Ian Dunham, Stephan Beck - Cell Reports 2016 cited by 147

  22. Constitutive NF-κB activation in AML: Causes and treatment strategies

    Authors: Matthieu Bosman, Jan Jacob Schuringa, Edo Vellenga - Critical Reviews in Oncology/Hematology 2015 cited by 105

  23. Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation

    Authors: Gerbrig Berger, Eva van den Berg, Birgit Sikkema‐Raddatz, Kristin M. Abbott, Richard J. Sinke, Laura Bungener, André B. Mulder, Edo Vellenga - Leukemia 2016 cited by 88

  24. Differential redox-regulation and mitochondrial dynamics in normal and leukemic hematopoietic stem cells: A potential window for leukemia therapy

    Authors: Katharina Mattes, Edo Vellenga, Hein Schepers - Critical Reviews in Oncology/Hematology 2019 cited by 60